Meeting
2020 ASCO Virtual Scientific Program
Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.
Authors
Margaret Ottaviano
Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy
Margaret Ottaviano , Marianna Tortora , Mario Giuliano , Daniela Terracciano , Vincenzo Di Lauro , Fernanda Picozzi , Sara Parola , Vittorio Riccio , Pietro De Placido , Erica Pietroluongo , Antonietta Liotti , Evelina La Civita , Gianluca Guggino , Marcellino Cicalese , Carlo Curcio , Michele Longo , Gerardo Botti , Bruno Daniele , Sabino De Placido , Giovannella Palmieri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Thymic Malignancies
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9074)
DOI
10.1200/JCO.2020.38.15_suppl.9074
Abstract #
9074
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.
First Author: Jose Carlos Benitez
Poster
2018 ASCO Annual Meeting
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.
First Author: Matteo Perrino
Poster
2021 ASCO Annual Meeting
Clinicogenomic characterization of metastatic thymic epithelial tumors.
First Author: Fatemeh Ardeshir-Larijani
Poster
2017 ASCO Annual Meeting
Molecular analysis of thymic epithelial tumors (TETs): A report by The Cancer Genome Atlas (TCGA) research network.
First Author: Patrick J. Loehrer Sr.